SCHEMBL6627674

SCHEMBL6627674

CCCc1ccncc1C(=O)CCl

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ PTGDR2 Q9Y5Y4 2/20 0.42
▸ KDM4C Q9H3R0 4/20 0.41
▸ KDM6B O15054 3/20 0.41
▸ CYP2E1 P05181 3/20 0.40
▸ CYP2C8 P10632 3/20 0.40
▸ CYP2D6 P10635 3/20 0.40
▸ CYP2A6 P11509 3/20 0.40
▸ CYP2C9 P11712 3/20 0.40
▸ CYP2B6 P20813 3/20 0.40
▸ CYP2C19 P33261 3/20 0.40
▸ SIRT3 Q9NTG7 1/20 0.38
▸ TDP1 Q9NUW8 1/20 0.38
▸ ALDH1A1 P00352 4/20 0.37
▸ LMNA P02545 1/20 0.37
▸ HTT P42858 1/20 0.37
▸ CYP1A2 P05177 2/20 0.37
▸ CYP3A4 P08684 2/20 0.37
▸ KDR P35968 1/20 0.36
▸ THRA P10827 1/20 0.36
▸ THRB P10828 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6626490 0.88 ALDH1A1 (0.43) KDM4CKDM6BCYP2E1CYP2C8CYP2D6
SCHEMBL258369 0.81 KDM4C (0.51) PTGDR2KDM4CKDM6BCYP2E1CYP2C8
SCHEMBL4734614 0.81 CYP2E1 (0.43) PTGDR2KDM4CKDM6BCYP2E1CYP2C8
Hydrochloric Acid SCHEMBL5739434 0.80 KDM4C (0.50) PTGDR2KDM4CKDM6BCYP2E1CYP2C8
SCHEMBL16610646 0.76 CYP2E1 (0.39) PTGDR2KDM4CKDM6BCYP2E1CYP2C8
SCHEMBL4974313 0.76 SIRT3 (0.59) PTGDR2KDM4CKDM6BCYP2D6CYP2C19
Hydrochloric Acid SCHEMBL3092651 0.75 SIRT3 (0.58) PTGDR2KDM4CKDM6BCYP2E1CYP2C8
SCHEMBL9517606 0.75 CYP2E1 (0.43) PTGDR2KDM4CKDM6BCYP2E1CYP2C8
SCHEMBL6627688 0.73 CYP2A6 (0.45) PTGDR2KDM4CKDM6BCYP2E1CYP2C8
SCHEMBL18599002 0.72 KDM6B (0.43) PTGDR2KDM4CKDM6BSIRT3TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20040267017-A1 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors BAYER PHARMACEUTICALS CORPORATION 2004-12-30 — — US disclosed
EP-1432706-A2 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS Bayer Pharmaceuticals Corporation (US) 2004-06-30 — — EP disclosed
WO-2003027085-A2 3-PYRIDYL OR 4-ISOQUINOLINYL THIAZOLES AS C17,20 LYASE INHIBITORS BAYER PHARMACEUTICALS CORPORATION (US) 2003-04-03 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040267017-A1 3-pyridyl or 4-isoquinolinyl thiazoles as c17, 20 lyase inhibitors CYP17A1, CYP21A2, HSD17B1 PTGDR2 2249/4885KDM4C 512/4885KDM6B 1223/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback